论文部分内容阅读
目的：探讨人胎肝细胞生长因子对肝硬化的治疗作用。方法：用人胎肝细胞生长因子肌肉注射治疗肝硬化５２例（治疗组），每日６ｍｇ，１０天为１疗程。对照组３４例，给予常规治疗。结果：经过１个疗程治疗后，治疗组的ＡＬＴ、胆红素比治疗前显著降低（Ｐ＜０．０５），清蛋白、凝血酶原活动度等指标比治疗前明显升高（Ｐ＜０．０５）；免疫指标仅ＩｇＧ、Ｃ３比治疗前有明显改变（Ｐ＜０．０５），但在治疗两个疗程后，各免疫指标（ＩｇＧ、ＩｇＡ、ＩｇＭ、Ｃ３）均有显著性改变（Ｐ＜０．０５），对照组治疗前后无明显改变。结论：提示加大人胎肝细胞因子的剂量或延长疗程会使肝硬化病情得到进一步改善。
Objective: To investigate the therapeutic effect of human fetal hepatocyte growth factor on cirrhosis. Methods: Fifty-two patients with liver cirrhosis were treated by intramuscular injection of human fetal hepatocyte growth factor (treatment group), 6mg daily for 10 days for one course of treatment. Control group of 34 patients, given conventional treatment. Results: After one course of treatment, ALT and bilirubin in the treatment group were significantly lower than those before treatment (P <0.05), and the indexes of albumin and prothrombin activity were significantly higher than those before treatment (P <0 (P <0.05). However, after the two courses of treatment, the immune indexes (IgG, IgA, IgM, C3) were significantly changed P <0.05), no significant change in the control group before and after treatment. Conclusion: It is suggested that increasing the dosage of human fetal hepatocyte factor or prolonging the course of treatment will further improve the condition of cirrhosis.